Market capitalization | $9.98m |
Enterprise Value | $5.96m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.47 |
P/S ratio (TTM) P/S ratio | 0.79 |
P/B ratio (TTM) P/B ratio | 0.26 |
Revenue growth (TTM) Revenue growth | 1,117.50% |
Revenue (TTM) Revenue | $12.59m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast AIkido Pharma Inc:
1 Analyst has issued a forecast AIkido Pharma Inc:
Sep '24 |
+/-
%
|
||
Revenue | 13 13 |
1,122%
1,122%
|
|
Gross Profit | 12 12 |
1,076%
1,076%
|
|
EBITDA | -14 -14 |
26%
26%
|
EBIT (Operating Income) EBIT | -15 -15 |
24%
24%
|
Net Profit | -23 -23 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.
Head office | United States |
CEO | Anthony Hayes |
Employees | 28 |
Founded | 1967 |
Website | www.dominariholdings.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.